Fig 1.
Flow chart of study participants.
Flow chart of study participants. FP: femoropopliteal; DCB: drug-coated balloon; EVT: endovascular therapy; MI: myocardial infarction.
Table 1.
Patient Demographics.
Table 2.
Lesion Characteristics.
Table 3.
Immediate Procedural Characteristics.
Fig 2.
Kaplan-Meier curves for freedom from binary restenosis.
(A) The 12-month binary restenosis-free rate is 77.5% for study participants. (B) A significant difference is noted between Trans-Atlantic Intersociety Consensus (TASC) II B (blue) and TASC C/D (green) lesions in the 12-month binary restenosis-free rate (90% vs. 71%, p = 0.025). (C) No significant differences are observed among the low- (blue), moderate- (gold), and high-risk (green) groups regarding the 12-month binary restenosis-free rates (60%, 84%, and 73%, p = 0.396). (D) The de novo (blue), restenosis (green), and in-stent restenosis (ISR) (gold) lesions have similar 12-month binary restenosis-free rates (79%, 75%, and 80%, p = 0.456).
Fig 3.
Kaplan-Meier curves for freedom from clinically driven target lesion revascularization (CD-TLR)
(A) The 12-month CD-TLR-free rate is 84.5% for study participants. (B) Compared to TASC II C/D lesions (green), TASC II B lesions (blue) have a higher 12-month CD-TLR-free rate (95% vs. 80%, p = 0.114). (C) No significant differences are observed among the low- (blue), moderate- (gold), and high-risk (green) groups in the 12-month CD-TLR-free rates (78%, 89%, and 80%, p = 0.635). (D) The de novo (blue), restenosis (green), and in-stent restenosis (ISR) (gold) lesions have similar 12-month CD-TLR-free rates (80%, 75%, and 80%, p = 0.807).
Table 4.
Multivariate analyses: predictors of binary restenosis and clinically driven target lesion revascularization (CD-TLR).